NIH Securing Funding Becomes a 'Pipe Dream' as Success Rates Plummet
March 26, 2026 · 2 min read
Jared Klein
For a growing number of biomedical researchers, securing an NIH grant has become what one scientist calls "a pipe dream." The agency awarded 5,564 fewer grants in fiscal year 2025 than 2024—an 8.6 percent drop—and early indicators suggest FY2026 will be worse.
As of March 3, NIH had issued 74 percent fewer new competitive awards than the average for the same period across fiscal years 2021 through 2024. The agency's $47.2 billion allocation for FY2026 represents only a 0.5 percent increase over the prior year. Adjusted for inflation, that is a real-dollar decrease that tightens paylines—the score thresholds required to secure funding—across every institute.
Sixteen Institutes Without Permanent Directors
Administrative upheaval compounds the funding squeeze. Sixteen of NIH's 27 institutes and centers currently lack permanent directors, a leadership vacuum that slows strategic direction and grant review processes. NIH Director Jay Bhattacharya said he is conducting two to four interviews weekly for senior positions and accelerating what is normally a years-long vetting process.
The agency also lost 22 percent of its staff through reductions last year, creating processing bottlenecks that have not been resolved. Grant officers managing larger portfolios with fewer colleagues report slower review cycles and correspondence delays.
Ideological Screening Adds New Uncertainty
Researchers report a less visible but equally disruptive shift: applications are now screened for ideologically misaligned language. Former NIH scientist Anna Culbertson noted that "there's so much beyond just the budget" affecting research funding decisions.
Brandon Schuff, a researcher navigating the current landscape, described federal grant funding as having become unreliable enough to force alternatives: "Due to the current political climate, obtaining federal" grants has become "a pipe dream," driving scientists toward industry partnerships and private funding.
Charting an Alternative Path
Researchers who have historically built careers on NIH R01 grants face a structural reckoning. With success rates at some institutes dropping below 4 percent, diversification is no longer optional. The DOE Office of Science, NSF cross-cutting programs, and SBIR/STTR mechanisms remain viable federal alternatives, while platforms like grantedai.com can surface foundation and international opportunities that align with specific research domains.